Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
Miscellaneous Services (Temporary Codes)
Q5103 is a valid 2024 HCPCS code for Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg or just “Injection, inflectra” for short, used in Medical care.
HCPCS Level II Code Miscellaneous Services (Temporary Codes) |
|
HCPCS Code | Q5103 |
---|---|
Description |
Long description:
Short description: |
HCPCS Modifier1 | |
HCPCS Pricing indicator |
51 - Drugs
|
Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
Coverage code | D - Special coverage instructions apply |
ASC payment group code | Effective Apr 01, 2018 - This procedure is approved to be performed in an ambulatory surgical center. |
BETOS2 code | O1E - Other drugs |
HCPCS Action code | N - No maintenance for this code |
Type of service | 1 - Medical care |
Effective date | Effective Apr 01, 2018 |
Date added | Added Apr 01, 2018 |
HCPCS Coding Procedures |
In HCPCS Level II, modifiers are composed of two alpha or alphanumeric characters.
Example: E0260-NU - Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress
“NU” identifies the hospital bed as new equipment
Effective | Code Dosage | Payment Limit |
Vaccine AWP % | Vaccine Limit | Infusion AWP % | DME infusion limit | Blood AWP % | Blood limit | Clotting factor | Note |
---|---|---|---|---|---|---|---|---|---|---|
October 1, 2024 - December 31, 2024 | 10 MG | 13.618 | - | - | - | - | - | - | ||
Jul 1, 2024 - Sep 30, 2024 | 10 MG | 10.663 | - | - | - | - | - | - | ||
April 1, 2024 - June 30, 2024 | 10 MG | 11.092 | - | - | - | - | - | - | ||
January 1, 2024 - March 31, 2024 | 10 MG | 14.294 | - | - | - | - | - | - | ||
October 1, 2023 - December 31, 2023 | 10 MG | 13.931 | 20% | - | - | - | - | - |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
8% of reference add-on applied
8% of reference add-on applied
8% of reference add-on applied
8% of reference add-on applied